Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. (2019)
Attributed to:
King's Health Partners Confidence in Concept
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s10549-019-05134-x
PubMed Identifier: 30656459
Publication URI: http://europepmc.org/abstract/MED/30656459
Type: Journal Article/Review
Volume: 174
Parent Publication: Breast cancer research and treatment
Issue: 3
ISSN: 0167-6806